Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873479 | 1.00 | LMNA (0.33) | LMNAMEN1ALDH1A1POLBKMT2A | |
| SCHEMBL17363051 | 0.98 | LMNA (0.30) | LMNA | |
| SCHEMBL15910747 | 0.94 | — | — | |
| SCHEMBL15900171 | 0.90 | — | — | |
| SCHEMBL1062985 | 0.84 | LMNA (0.39) | LMNAMEN1ALDH1A1POLBKMT2A | |
| SCHEMBL23214646 | 0.82 | KDM4E (0.30) | KMT2A | |
| SCHEMBL1952922 | 0.82 | — | — | |
| SCHEMBL1930225 | 0.80 | DPP4 (0.31) | — | |
| SCHEMBL18492755 | 0.78 | EPHX1 (0.34) | — | |
| SCHEMBL15910863 | 0.78 | USP2 (0.32) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475803-B2 | Sweet flavor modifier | SENOMYX, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150376176-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. | 2015-12-31 | — | — | US | disclosed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| EP-2185537-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1551829-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035569-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | LMNA 1514/4885MEN1 2654/4885ALDH1A1 2600/4885 |
| US-20150376176-A1 | SWEET FLAVOR MODIFIER | TAS2R5, TAS2R10, TAS2R50 | LMNA 4233/4885MEN1 1566/4885ALDH1A1 589/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | LMNA 1347/4885MEN1 2257/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.